<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xml:base="http://harvardscience.harvard.edu" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
 <title>all Tomas Kirchhausen stories</title>
 <link>http://harvardscience.harvard.edu/stories/person/1856</link>
 <description>Stories and external links referencing a person (RSS)</description>
 <language>en</language>
<item>
 <title>Synthetic molecule blocks exit from cell organelle</title>
 <link>http://harvardscience.harvard.edu/foundations/articles/synthetic-molecule-blocks-exit-cell-organelle</link>
 <description>&lt;!--paging_filter--&gt;&lt;p&gt;The ubiquitous, small GTPases are a family of signal  transduction molecules that play crucial roles in numerous  biological processes, including cell motility and division. Though  scientists have eyed these proteins as potential therapeutic  targets for years, inhibitors of GTPases have proven exceedingly  difficult to develop; currently there are only a handful in  existence. But in  a Nov. 20, 2005 advanced online publication in  Nature Chemical Biology,Tom Kirchhausen, Matthew Shair, and  Henry Pelish have revealed a new class of GTPase inhibitor. They  have synthesized secramine, a small molecule that blocks the  GTPase Cdc42, which is crucial for vesicular transport and cell  migration. The finding provides a new means to study protein  traffic from the Golgi apparatus and offers hope that unique and  specific GTPase inhibitors might one day be used to treat  disease.&lt;/p&gt;
</description>
 <pubDate>Mon, 26 Mar 2007 05:43:14 -0400</pubDate>
 <dc:creator>70652986</dc:creator>
 <guid isPermaLink="false">3585 at http://harvardscience.harvard.edu</guid>
</item>
</channel>
</rss>
